Global Multi-Modal Spatial Omics Platforms Market Size is valued at USD 174.23 Mn in 2024 and is predicted to reach USD 504.55Mn by the year 2034 at a 11.4% CAGR during the forecast period for 2025 to 2034.
Multi-Modal Spatial Omics Platforms Market, Share & Trends Analysis Report, By Multi-Omic Combination (RNA + Protein, Protein + Metabolite/Lipid, RNA + DNA / Genomic features, Tri-modal (RNA + Protein + Morphology/Metabolite)), By Detection Modality (In situ imaging (cyclic IF, fluorescence), In situ hybridization / in situ sequencing, ROI-based digital spatial profiling, Imaging mass cytometry/ion beam imaging, Barcoding-based spatial transcriptomics), By Workflow Component, By Sample Type, By Spatial Resolution, By Multiplexing Capacity, By Application, By End-User, By Region, and Segment Forecasts, 2025 to 2034
Multi-modal spatial omics platforms integrate multiple molecular layers—such as RNA, protein, and metabolites—within the same tissue section while preserving spatial context. By combining techniques like spatial transcriptomics, multiplex immunofluorescence, and imaging mass spectrometry, these platforms reveal how different biomolecules interact within intact cellular environments. This holistic approach enables researchers to study cell-to-cell communication, tissue organization, and disease mechanisms in unprecedented detail, bridging molecular biology, imaging, and data analytics into a single, unified workflow.
Multi-modal spatial omics platforms allow researchers to analyze genes, proteins, and other molecules within their native tissue context, transforming tissue analysis from bulk sampling to in situ cellular mapping. The market is entering a phase of rapid expansion as spatial proteomics, high-plex imaging, and whole-transcriptome mapping emerge as key growth areas. Driven by rising R&D in immuno-oncology, neuroscience, and precision pathology, these platforms are becoming central to biomarker discovery, drug target validation, and the evolution of quantitative, spatially informed diagnostics.
Some of the Major Key Players in the Multi-Modal Spatial Omics Platforms Market are
The multi-modal spatial omics platforms market is segmented into multi-omic combination, detection modality, workflow component, sample type, spatial resolution, multiplexing level, application, and end-user. Based on the multi-omic combination, the market is segmented into RNA + protein, protein + metabolite/lipid, RNA + DNA / genomic features, and tri-modal (RNA + protein + morphology/metabolite). Based on the detection modality, the market is divided into in situ imaging (cyclic if, fluorescence), in situ hybridization / in situ sequencing, ROI-based digital spatial profiling, imaging mass cytometry/ion beam imaging, and barcoding-based spatial transcriptomics.
Based on the workflow component, the market is divided into instruments/platforms, reagents & panels, software/analytics, and services/CROs. Based on the sample type, the market is divided into subcellular, single-cell, and spot-level / ROI. Based on the multiplexing capacity, the market is divided into Low-plex (< 100 targets), Mid-plex (100 – 1,000 targets), High-plex (> 1,000 targets or whole-transcriptome. Based on the application, the market is divided into immuno-oncology / tumor microenvironment, biomarker discovery, neuroscience, inflammation & autoimmune, infectious diseases, and fibrosis. Based on the End-User, the market is divided into pharma & biotech, academic & research institutes, cros & service providers, hospitals & pathology labs.
The integration of RNA and protein analysis within multi-modal spatial omics platforms is a key growth driver, offering a holistic view of cellular function, tissue organization, and disease mechanisms at unparalleled resolution. Spatial transcriptomics maps gene expression within its native tissue context, revealing how genes behave in specific cell types or locations. Combining RNA and protein profiling enables the discovery of novel biomarkers and therapeutic targets, supporting precision medicine and advancing targeted drug development, particularly in complex areas such as tumor microenvironment research.
FFPE samples remain the cornerstone of clinical diagnostics and biobanking due to their global availability and stability. Their widespread use allows researchers to conduct retrospective spatial omics studies without the need for new tissue collection, reducing costs and logistical hurdles. FFPE’s dominance in pathology and oncology stems from its compatibility with RNA and protein mapping, enabling biomarker discovery and tumor microenvironment analysis. Ongoing improvements in RNA retrieval and antibody-based detection continue to enhance its value in multi-modal spatial omics.
North America is home to prestigious colleges and renowned research organisations like the National Institutes of Health, which create an atmosphere that is favourable for advances in spatial omics. By consistently creating and improving cutting-edge spatial omics platforms, well-known American businesses like 10x Genomics and NanoString Technologies have made a substantial contribution to the market. Research and the commercialization of these technologies have been further pushed by government financing programs and initiatives, such as those from the National Cancer Institute. North America is now a centre for precision medicine and advanced diagnostics due to the combination of strong regulatory frameworks and advantageous trade policies, which have also boosted market expansion.
· In October 2025, SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and 10x Genomics, Inc. announced a strategic partnership to provide automated workflows for single cell research. The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform, with planned future expansion to the Visium Spatial platform, by providing plug-and-play protocols on SPT Labtech’s firefly® liquid handling platform.
· In October 2025, Bruker announced FDA clearance of claims 7 and 8 for the MALDI Biotyper® CA System, expanding diagnostic capabilities. The MALDI Biotyper CA System is a mass spectrometry-based platform that uses MALDI-TOF technology for rapid identification of microorganisms following culture from human specimens, either from isolated colonies or positively flagged blood cultures.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 174.23 Mn |
| Revenue Forecast In 2034 | USD 504.55 Mn |
| Growth Rate CAGR | CAGR of 11.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Multi-Omic Combination, Detection Modality, Workflow Component, Sample Type, Spatial Resolution, Multiplexing Complex, Application, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
| Competitive Landscape | 10x Genomics, Bruker (NanoString assets), Vizgen, Miltenyi Biotec, Standard BioTools (Fluidigm), Ionpath, Lunaphore (now part of Bio-Techne), Bio-Techne / ACD, Curio Bioscience, Akoya Biosciences, Molecular Instruments (HCR), Ultivue, Other prominent players |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Multi-Modal Spatial Omics Platforms Market- By Multi-Omic Combination
· RNA + Protein
· Protein + Metabolite/Lipid
· RNA + DNA / Genomic features
· Tri-modal (RNA + Protein + Morphology/Metabolite)
· In situ imaging (cyclic IF, fluorescence)
· In situ hybridization / in situ sequencing
· ROI-based digital spatial profiling
· Imaging mass cytometry/ion beam imaging
· Barcoding-based spatial transcriptomics
Global Multi-Modal Spatial Omics Platforms Market – By Workflow Component
· Instruments/Platforms
· Reagents & Panels
· Software/Analytics
· Services/CROs
Global Multi-Modal Spatial Omics Platforms Market- By Sample Type
· FFPE
· Fresh Frozen
· Organoids / Cells
Global Multi-Modal Spatial Omics Platforms Market – By Spatial Resolution
· Subcellular
· Single-cell
· Spot-level / ROI
Global Multi-Modal Spatial Omics Platforms Market – By Multiplexing Capacity
· Low-plex (< 100 targets)
· Mid-plex (100 – 1,000 targets)
· High-plex (> 1,000 targets or whole-transcriptome)
Global Multi-Modal Spatial Omics Platforms Market – By Application
· Immuno-oncology / Tumor Microenvironment
· Biomarker discovery
· Neuroscience
· Inflammation & Autoimmune
· Infectious Diseases
· Fibrosis
Global Multi-Modal Spatial Omics Platforms Market – By End-User
· Pharma & Biotech
· Academic & Research Institutes
· CROs & Service Providers
· Hospitals & Pathology Labs
Global Multi-Modal Spatial Omics Platforms Market – By Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Multi-Modal Spatial Omics Platforms Market Snapshot
Chapter 4. Global Multi-Modal Spatial Omics Platforms Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Multi-Modal Spatial Omics Platforms Market Industry Trends
4.10. Global Multi-Modal Spatial Omics Platforms Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Multi-Modal Spatial Omics Platforms Market Segmentation 1: By Multi-Omic Combination, Estimates & Trend Analysis
5.1. Market Share by Multi-Omic Combination, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Multi-Omic Combination:
5.2.1. RNA + Protein
5.2.2. Protein + Metabolite/Lipid
5.2.3. RNA + DNA / Genomic features
5.2.4. Tri-modal (RNA + Protein + Morphology/Metabolite)
Chapter 6. Multi-Modal Spatial Omics Platforms Market Segmentation 2: By Detection Modality, Estimates & Trend Analysis
6.1. Market Share by Detection Modality, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Detection Modality:
6.2.1. In situ imaging (cyclic IF, fluorescence)
6.2.2. In situ hybridization / in situ sequencing
6.2.3. ROI-based digital spatial profiling
6.2.4. Imaging mass cytometry/ion beam imaging
6.2.5. Barcoding-based spatial transcriptomics
Chapter 7. Multi-Modal Spatial Omics Platforms Market Segmentation 3: By Workflow Component, Estimates & Trend Analysis
7.1. Market Share by Workflow Component, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Workflow Component:
7.2.1. Instruments/Platforms
7.2.2. Reagents & Panels
7.2.3. Software/Analytics
7.2.4. Services/CROs
Chapter 8. Multi-Modal Spatial Omics Platforms Market Segmentation 4: By Sample Type, Estimates & Trend Analysis
8.1. Market Share by Sample Type, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Sample Type:
8.2.1. FFPE
8.2.2. Fresh Frozen
8.2.3. Organoids / Cells
Chapter 9. Multi-Modal Spatial Omics Platforms Market Segmentation 5: By Spatial Resolution, Estimates & Trend Analysis
9.1. Market Share by Spatial Resolution, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Spatial Resolution:
9.2.1. Subcellular
9.2.2. Single-cell
9.2.3. Spot-level / ROI
Chapter 10. Multi-Modal Spatial Omics Platforms Market Segmentation 6: By Multiplexing Capacity, Estimates & Trend Analysis
10.1. Market Share by Multiplexing Capacity, 2024 & 2034
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Multiplexing Capacity:
10.2.1. Low-plex (< 100 targets)
10.2.2. Mid-plex (100 – 1,000 targets)
10.2.3. High-plex (> 1,000 targets or whole-transcriptome)
Chapter 11. Multi-Modal Spatial Omics Platforms Market Segmentation 7: By Application, Estimates & Trend Analysis
11.1. Market Share by Application, 2024 & 2034
11.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
11.2.1. Immuno-oncology / Tumor Microenvironment
11.2.2. Biomarker discovery
11.2.3. Neuroscience
11.2.4. Inflammation & Autoimmune
11.2.5. Infectious Diseases
11.2.6. Fibrosis
Chapter 12. Multi-Modal Spatial Omics Platforms Market Segmentation 8: By End-User, Estimates & Trend Analysis
12.1. Market Share by End-User, 2024 & 2034
12.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
12.2.1. Pharma & Biotech
12.2.2. Academic & Research Institutes
12.2.3. CROs & Service Providers
12.2.4. Hospitals & Pathology Labs
Chapter 13. Multi-Modal Spatial Omics Platforms Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. Global Multi-Modal Spatial Omics Platforms Market, Regional Snapshot 2024 & 2034
13.2. North America
13.2.1. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
13.2.1.1. US
13.2.1.2. Canada
13.2.2. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multi-Omic Combination, 2021-2034
13.2.3. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Detection Modality, 2021-2034
13.2.4. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
13.2.5. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Sample Type, 2021-2034
13.2.6. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Spatial Resolution, 2021-2034
13.2.7. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multiplexing Capacity, 2021-2034
13.2.8. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
13.2.9. North America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by End-User2021-2034
13.3. Europe
13.3.1. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
13.3.1.1. Germany
13.3.1.2. U.K.
13.3.1.3. France
13.3.1.4. Italy
13.3.1.5. Spain
13.3.1.6. Rest of Europe
13.3.2. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multi-Omic Combination, 2021-2034
13.3.3. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Detection Modality, 2021-2034
13.3.4. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
13.3.5. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Sample Type, 2021-2034
13.3.6. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Spatial Resolution, 2021-2034
13.3.7. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multiplexing Capacity, 2021-2034
13.3.8. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
13.3.9. Europe Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
13.4. Asia Pacific
13.4.1. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
13.4.1.1. India
13.4.1.2. China
13.4.1.3. Japan
13.4.1.4. Australia
13.4.1.5. South Korea
13.4.1.6. Hong Kong
13.4.1.7. Southeast Asia
13.4.1.8. Rest of Asia Pacific
13.4.2. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multi-Omic Combination, 2021-2034
13.4.3. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Detection Modality, 2021-2034
13.4.4. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts Workflow Component, 2021-2034
13.4.5. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Sample Type, 2021-2034
13.4.6. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Spatial Resolution, 2021-2034
13.4.7. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multiplexing Capacity, 2021-2034
13.4.8. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
13.4.9. Asia Pacific Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
13.5. Latin America
13.5.1. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
13.5.1.1. Brazil
13.5.1.2. Mexico
13.5.1.3. Rest of Latin America
13.5.2. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multi-Omic Combination, 2021-2034
13.5.3. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Detection Modality, 2021-2034
13.5.4. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
13.5.5. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Sample Type, 2021-2034
13.5.6. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Spatial Resolution, 2021-2034
13.5.7. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multiplexing Capacity, 2021-2034
13.5.8. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
13.5.9. Latin America Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
13.6. Middle East & Africa
13.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
13.6.1.1. GCC Countries
13.6.1.2. Israel
13.6.1.3. South Africa
13.6.1.4. Rest of Middle East and Africa
13.6.2. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multi-Omic Combination, 2021-2034
13.6.3. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Detection Modality, 2021-2034
13.6.4. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Workflow Component, 2021-2034
13.6.5. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Sample Type, 2021-2034
13.6.6. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Spatial Resolution, 2021-2034
13.6.7. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Multiplexing Capacity, 2021-2034
13.6.8. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
13.6.9. Middle East & Africa Multi-Modal Spatial Omics Platforms Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. 10x Genomics
14.2.1.1. Business Overview
14.2.1.2. Key Multi-Omic Combination/Service Overview
14.2.1.3. Financial Performance
14.2.1.4. Geographical Presence
14.2.1.5. Recent Developments with Business Strategy
14.2.2. Vizgen
14.2.3. Miltenyi Biotec
14.2.4. Standard BioTools (Fluidigm)
14.2.5. Ionpath
14.2.6. Lunaphore (now part of Bio-Techne)
14.2.7. Bio-Techne / ACD
14.2.8. Curio Bioscience
14.2.9. Akoya Biosciences
14.2.10. Molecular Instruments (HCR)
14.2.11. Ultivue
14.2.12. Other prominent players